.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Fortis Healthcare recently released its Fortis Healthcare Q3 results, showing a 22% year-on-year decline in consolidated profit. Although the profit after tax (PAT) reached Rs 197 crore, this figure dropped from Rs 254 crore in the year-ago period. Consequently, the financial landscape reflects both significant operational hurdles and strong underlying revenue growth across its hospital network.
The reported profit includes a net exceptional loss of Rs 45.9 crore. Primarily, this loss stems from a one-time impact related to new labour codes. Moreover, the company balanced this against a reversal of impairment in an associate firm of Rs 9.4 crore. Meanwhile, revenue performed exceptionally well, increasing to Rs 2,265 crore compared to Rs 1,928 crore in the prior fiscal year. Therefore, the core business remains robust despite the temporary bottom-line pressure caused by regulatory adjustments.
Fortis Healthcare MD and CEO, Ashutosh Raghuvanshi, highlighted healthy growth in key specialties during the quarter. Specifically, renal sciences and orthopedics grew by 27% and 20%, respectively, over the previous period. Furthermore, the company is actively expanding its footprint in Bengaluru through recent acquisitions. This move strengthens its presence from 900 beds to a potential capacity of over 1,500 beds. Additionally, management is evaluating further inorganic opportunities within existing clusters to sustain clinical momentum.
Q1: What caused the decline in Fortis Healthcare\'s Q3 net profit?
The profit decline was primarily due to an exceptional loss of Rs 45.9 crore, which was linked to the one-time impact of new labour codes.
Q2: How did the revenue perform during the December 2025 quarter?
Revenue increased significantly to Rs 2,265 crore, representing a healthy rise from Rs 1,928 crore in the same quarter of the previous year.
Q3: Which medical specialties saw the most growth in this period?
Renal sciences and orthopedics were the top-performing specialties, growing by 27% and 20% respectively, indicating high demand for these clinical services.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Fortis Healthcare reported a 22% dip in Q3 profit to Rs 197 crore, impacted by one-time labour code costs, despite a strong 17.5% rise in consolidated reven...
8 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
